CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 291 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01672970
NCT01672970N/ACompleted
CompareCT.gov

Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With Tocilizumab.

Hoffmann-La Roche·observational·Posted Aug 27, 2012·Updated Mar 28, 2016

In Brief

An observational study for Rheumatoid Arthritis. Completed, enrolled 291 participants across 20 sites.

Detailed Summary

This multi-center observational study will evaluate the use of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the local label will be followed for 6 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesHungary
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 27, 2012
Enrollment StartJul 1, 2012
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.8 years ago